Supernus Pharmaceuticals | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (26)

Latest Posts

About This Stock More About This Stock
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
Article By: Rod Raynovich
Sunday, February 5, 2023 8:10 PM EST
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
In this article: NTLA, IBB, PACB, XBI, SUPN, CRSP, ARKG, VCYT Also: CYRX, GERN, QDEL, HOLX, VRTX, EXAS, EVH, NVTA, TDOC
Read
Stocks That Made New Highs On Friday, Aug. 19
Article By: Fred Fuld III
Sunday, August 21, 2022 5:46 AM EST
On Friday, in spite of the stock market being down, there were several stocks that actually made new highs.
In this article: NL, ARTNA, ICPT, SUPN, ADMA, AXSM
Read
Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?
Article By: Zacks Investment Research
Monday, February 21, 2022 5:33 AM EST
Supernus Pharmaceuticals shares soared 5.7% in the last trading session to close at $32.90. The move was backed by solid volume with far more shares changing hands than in a normal session.
In this article: SUPN Also: FIXX
Read
4 Mental Health Stocks Got My Mind Made Up
Article By: Sunil Tinani
Friday, November 13, 2020 4:45 AM EST
The WHO has urged nations to increase their investment in mental healthcare services, or risk facing an upsurge of cases. Biotech and service companies in the mental healthcare niche are expected to do well in the medium to long term.
In this article: ITCI, ACHC, SUPN, GWPH
Read
How To Identify Short Candidates Through Anomalous Insider Selling Activity
Article By: Sabrient Systems
Tuesday, January 7, 2020 11:03 PM EST
Perhaps the most reliable shortcut to identifying a company at elevated risk of a downturn in its share price is looking at how executives and directors use their equity instruments.
In this article: SUPN, USM, MGLN, AMRN, OSUR, MYRG
Read

Latest Tweets for $SUPN

No tweets yet!

PARTNER HEADLINES